Re: Hemorrhages During Escitalopram-VenlafaxineMirtazapine Combination Treatment of Depression
Dear Editor: The publication of Dr Benazzi's case report (1) is somewhat worrying. Although the report does not suggest that the treatment in this case is routine or normal practice, the concluding statement that "clinicians should take care when combining several antidepressants that increase serotonin" appears to condone the treatment outlined in the paper. Apart from the fact that all treatment algorithms for resistant depression recommend lithium augmentation prior to combined antidepressants, which in most cases come well down the list of strategies, given the limited evidence base for this intervention, and putting aside the fact that, when recommended, the combination of antidepressants refers to 2 antidepressants, to add 2 antidepressants at once to an alreadyprescribed antidepressant is to court disaster. That nasal and rectal bleeding were the only consequences of this dangerous cocktail could be viewed as fortunate. What level of hemoglobin this patient bled down to is not revealed in the report, and it must be presumed that this was checked and was not of great concern. What is of concern is the risk that this report will encourage this sort of prescribing.
Reply: Hemorrhages During Escitalopram-VenlafaxineMirtazapine Combination Treatment of Depression
Dear Editor: I thank Dr Al-Adwani for his comments on the treatment of resistant depression, as the topic is a hot one. There are several guidelines on the treatment of depression, which should be distinguished as bipolar disorder I, bipolar disorder II, and major depressive (unipolar) disorder. Among these disorders, the treatment of bipolar II depression is the most understudied, even if bipolar II depression is at least as common as unipolar depression in nontertiary care outpatients (1, 2) . The several guidelines on the treatment of bipolar and unipolar depression follow different steps. What matters most is that these guidelines are the result of a consensus among academic experts, based on literature reviews and personal opinions, not on data from usual clinical practice. The result is that these guidelines are detached from real-world clinical practice (described as an "often irrelevant evidence base" for clinical practice; 3). Even if we rely on the evidence we can find in the literature, this is of little help; at most it may guide the choice of a second antidepressant when the first one has failed. I have been in clinical practice for 21 years with the National Health Service as part-time consultant and with my private outpatient practice. In this latter setting (which is also the setting of most of my studies), I have thousands of visits yearly. Patients often come to see me after the failure of 1 or 2 antidepressants. When lithium was more in fashion than today, in the 1980s and early 1990s, I used it to boost antidepressants, but the results were often negative. (This difference between literature evidence on the efficacy of lithium added to antidepressants and clinical practice evidence has been reported; see 3.) When some monotherapy trials of antidepressants fail in unipolar depression, most clinicians combine 2 antidepressants with different actions (for example, fluoxetine and desipramine), but this step may fail. Next, a combination of antidepressants with different mechanisms of action may also be tried. The steps I follow in the highly treatment-resistant unipolar depressions (which are different from the steps to be followed in bipolar II depression and in bipolar I depression) are the following: If I get some improvement with 1 full-dose antidepressant, I add a second one with different biological actions. If this combination works but depression still impairs functioning, I prefer to keep the advantage reached at this stage and to proceed by adding a third antidepressant. If I changed the first or the second antidepressant when I added the third one, I would run the risk of losing the improvement achieved with the first 2 antidepressants if the third antidepressant did not work. As these depressions continue for months, a deterioration of clinical status is very painful (and risky) for these patients. By carefully titrating dosages, I have rarely seen mild serotonin syndromes and mild cardiovascular side effects. When people have this painful (and suicidal) state of multiple antidepressant-resistant depression, I have to do what seems logical to me in the absence of research evidence available for clinical practice. If I wanted to stay on the safe side (legally), I could use 1 antidepressant after the other, taking years to try all of them! The hopelessness of a person living with a severe depression for many months is great, and the suicide risk is also high. As clinicians (not as researchers), it is our duty to save the lives of these people and to dare to go beyond the reassuring (but not based on clinical practice evidence) guidelines when we have to treat a severe, suicidal depression. ECT would be a useful step, of course, but it is not readily available in Italy. 
Re: Case Reports as Letters Should Stay in The Canadian Journal of Psychiatry
Dear Editor: The debate on the subject of publishing case reports, initiated by Dr Margolese (1) with the editor-in-chief of our Journal, Dr Paris (2), deserves attention. I agree with Dr Paris's concern about reinforcing the Journal's impact by revising the publication criteria and methods. However, I support Dr Margolese in his concern that the case reports category will eventually disappear, even as letters to the editor. His argument is well presented. I would like to point out that eliminating case reports does not render any service to research or to practice; rather, it dispossesses a clinical knowledge that contrasts with the evidence-based medicine design currently used. Those of us in psychiatry claim that our knowledge is solid because it is based on evidence-based medicine. Nonetheless, we are not rich enough in our knowledge to discard case reports. Unless I do not read the same literature as today's psychiatrists, all our knowledge on clinical and therapeutic data is fragile: antipsychotics, antidepressants, cognitive-behavioral therapies, lithium, and cholinesterase inhibitors have not drastically improved the destinies of our patients. Metaanalyses dictate their effectiveness or their efficiency, which in general ranges from weak to moderate (3, 4) . The more one deals with long-course diseases, the more the data are far from convincing. As for side effects, the literature is close to "evidence-biased" medicine (5) . Thus, the single case report is often the first sign of alarm, for example, in reported cases of agranulocytosis, ablastic anemia, and hepatic failure. In addition, a well-established epistemology of single cases is already used in neuropsychology and cognitive neurosciences. These case reports, validated with the "single case study methodology," produced major successive publications that our psychiatric discipline could not possibly be indifferent to. It would have been regrettable had Paul Broca's case presenting Tan Tan, which revolutionized neurology, not been accepted for publication (6), or had Brenda Milner's case reports with HM, which revolutionized neuropsychology of the memory and learning, not been published (7) . The diagnoses of Capgras or Asperger syndromes, for instance, began with case reports, not as de novo classified syndromes. I personally believe that the CJP would not lose prestige if such cases were published. In addition, I believe that in Canada we have many clinicians like Broca and Milner who could make outstanding findings using single-case methodology. This argument is on especially firm ground for rare cases. Worth mentioning, the DSM-IV did not succeed in eliminating rare cases, nor has the DSM-V prelude project (www.dsm5.org). The idiosyncrasy is to psychiatry what a diamond is to geology.
